Search

Search Constraints

You searched for: Author/Creator Drake, Charles G

Search Results

2. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). (4th November 2015)

4. Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (4th November 2015)

5. Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. (4th November 2015)

7. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. (7th March 2020)

8. BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. Issue 2 (10th December 2021)

9. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Issue 1 (January 2018)